Irish sufferers of Migraine could be able to access a new drug to prevent its onset, said Brian Hayes MEP.
“The European Medicines Agency has recommended granting a marketing authorisation for Emgality, a preventative drug, and this will now be considered by the European Commission.
“It is estimated that approximately 15% of the population in the European Union suffers from migraine, including approximately half a million people in Ireland. Many people also experience nausea, vomiting and increased sensitivity to light or sound. Migraine can substantially impair a patient’s ability to function physically, at work or school, and socially.
“Emgality, once made available, will be administered to patients by injection, and is intended only for patients who have at least 4 migraine days per month. The benefits and safety of Emgality were studied in three pivotal trials involving 1,780 patients with good results. For patients with chronic migraine, the reduction was 2 days.
“As sufferers will know, there is no cure for migraine. Existing preventative treatments don’t always work well and some have unpleasant side effects.
“The European Commission is expected to decide on whether this drug should be distributed within the next two months and Department of Health officials need to keep a close eye on this.
“The distribution of these drugs will widen the choice of therapeutic options for patients and greatly improve chronic sufferers’ quality of life, so I will be calling on the Irish Government to fast-track the circulation of this drug so those who need it most, get it.”